Patients must not have any co-existing condition that would preclude full compliance with the study; no prior history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80

Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.

Patients with hypersensitivity to albumin are not eligible

Known hypersensitivity to 5-fluorouracil/leucovorin

Known hypersensitivity to irinotecan

Known hypersensitivity to any component of bevacizumab

Patients with a known hypersensitivity to olaparib or any of the excipients of the product

Patients with a known hypersensitivity to the combination/comparator agent

Known hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80 and Cremophor EL

Patients must not have any known previous or concurrent condition suggesting susceptibility to hypersensitivity or allergic reactions, including, but not limited to: known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies; patients with mild or seasonal allergies may be included after discussion with the study chairs

Patients must not have any history of hypersensitivity to any drugs or metabolites of midostaurin

Any previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatment

No history of hypersensitivity active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib

No known history of severe hypersensitivity reactions to any of the components of efatutazone or paclitaxel formulations

Patients with known hypersensitivity to any TZD oral agents are not eligible

Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization

Known hypersensitivity to any component of the formulation or substituted benzimidazoles

Known intolerance to either of the study drugs (or any of the excipients)

Patient has a known hypersensitivity to any of the components of the study drug

Patients with a known hypersensitivity to olaparib, temozolomide or any of the excipients of the products

Patients with a history of hypersensitivity to nickel

Patients with known hypersensitivity to any component of the chemotherapy regimen will not be eligible

Known hypersensitivity to gemcitabine, azacytidine or cytosine arabinoside

Known hypersensitivity to any component of bevacizumab

Known hypersensitivity to any oligodeoxynucleotide.

Patients with a known hypersensitivity to olaparib or any of the excipients of the product

History of hypersensitivity to active or inactive excipients of AZD5363, fulvestrant and enzalutamide or drugs with a similar chemical structure or class to these agents

Hypersensitivity to nivolumab, ipilimumab, or any of their excipients

Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 grade >= 3) that could interfere with study endpoints or put patient safety at risk

Known hypersensitivity to any of the excipients of ribociclib

Prior history of hypersensitivity, drug or radiation-induced, or other immune-mediated pneumonitis

Known hypersensitivity to any component of the atezolizumab or cobimetinib formulations

Documented progression on and/or intolerance/hypersensitivity to both paclitaxel and irinotecan (Part B only)

History of hypersensitivity to any of the additives in the alectinib drug formulation

Hypersensitivity to pembrolizumab or history of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)

Hypersensitivity to carboplatin or cisplatin

Known hypersensitivity to the components of MM-310, or docetaxel

History of prior >= grade 3 hypersensitivity to either brentuximab vedotin or nivolumab

Known hypersensitivity to Apatinib or components of the formulation.

Known hypersensitivity to any of the study drugs

History of hypersensitivity to durvalumab or tremelimumab or any excipients of these drugs.

Known hypersensitivity to any study drug component

Subject with a history of severe hypersensitivity reactions to any of the other excipients of the protocol IMPs (see Section 8.1.1);

Hypersensitivity to the active substance or to any of the excipients

Known hypersensitivity to any component of required drugs in the study

Known hypersensitivity to any of the components of RO6874281

For Part B exclusively, known hypersensitivity to any of the components of trastuzumab

For Part C exclusively, known hypersensitivity to any of the components of cetuximab

Patients with a known hypersensitivity to olaparib or any of the excipients of the product

Patients with a known hypersensitivity to the combination/comparator agent

Hypersensitivity to taxanes (such as Steven Johnson syndrome). Hypersensitivity, such as rash < Grade 3 that is managed, is allowed.

Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients

Patients with a known hypersensitivity to carboplatin

Patient has a known hypersensitivity to any of the excipients of LEE011

Patient has a known hypersensitivity to ribociclib or any of its excipients, or prior treatment with CDK 4/6 inhibitor

Hypersensitivity to:

History of hypersensitivity to iodine

Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

Subjects with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients

Patients with known hypersensitivity to any of the components of CBL0137;

Known hypersensitivity to drugs chemically related to tivozanib hydrochloride or sunitinib or their excipients

Known hypersensitivity to sunitinib or masitinib or to any of the excipients

Known hypersensitivity to afatinib, cisplatin, or pemetrexed

Patients who have had hypersensitivity to paclitaxel or any of its excipients

Subjects with a hypersensitivity to sirolimus.

Has a known severe hypersensitivity (? Grade 3) to any of the study chemotherapy agents and/or to any of their excipients.

Have previously participated in any study involving a checkpoint kinase 1 inhibitor or have hypersensitivity to the study drug or excipients.

Known hypersensitivity to the components of niraparib components or their formulation excipients

Prior exposure to a pyrrolobenzodiazepine or indolino-benzodiazepine based drug, or known hypersensitivity or contraindication to SC-005 or excipient contained in the drug formulation.

Previously identified hypersensitivity to components of the formulations used in this study

Known hypersensitivity to exemestane or its excipients

Hypersensitivity to nivolumab or any of its excipients.

Hypersensitivity to NKTR-214 or any of its excipients.

No history of severe hypersensitivity reaction to Cremophor EL

Participant has a known hypersensitivity to any of the excipients of H3B-6545.

Known hypersensitivity to ferumoxytol or any of its components

Known intolerance to study drug (or any of the excipients) and/or known hypersensitivity to rapamycins (eg, sirolimus, everolimus, temsirolimus) or any of the excipients

Known hypersensitivity to one or more of the study agents used

Patient has a known hypersensitivity to any of the excipients of ribociclib or everolimus

Known hypersensitivity to any study related agent excipient(s)

Known hypersensitivity to platinum compounds

Those with porphyria or with known hypersensitivity to porphyrins or porphyrin-like compounds

Documented hypersensitivity reaction to any product with GSE

History of, or known, hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system.

History of, or known, hypersensitivity to gemcitabine or platinum-containing compounds.

Subjects with known allergies, hypersensitivity, or intolerance to niraparib or its excipients

History of hypersensitivity to tremelimumab, durvalumab, or any excipient

Patient has a known hypersensitivity to any of the excipients of LEE011 or everolimus

Prior hypersensitivity to any of the components of the study drugs

Known hypersensitivity to afatinib or the excipients of any of the trial drugs

Patients with a known hypersensitivity to everolimus or other rapamycins (e.g. sirolimus, temsirolimus)

Patients with hypersensitivity to bortezomib, boron or mannitol.

Combination Arm: hypersensitivity to trastuzumab

Known hypersensitivity to gemcitabine, taxanes or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the product or comparator Summary of Product Characteristics or Prescribing Information. Possible hypersensitivity to napabucasin or one of the excipients which include the azo dyes sunset yellow and allura red.

History of severe hypersensitivity to study treatment excipients and additives or other monoclonal antibodies (mAbs) and/or their excipients.

Porphyria or known hypersensitivity to Photofrin® or porphyrin-like compounds or to any of its excipients

History of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in drug formulation

History of hypersensitivity to sertraline

Patients must not be known to have hypersensitivity to cisplatin, gemcitabine, or celecoxib

Patients with a known hypersensitivity to any excipient contained in the drug formulation

Any history of hypersensitivity to irinotecan

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to tremelimumab or any excipient

Patients with known hypersensitivity to any of the excipients of INC280 (crospovidone, mannitol, microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide, and various coating premixes)

History of hypersensitivity to AZD4635 or drugs with a similar chemical structure or class to AZD4635.

Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)

Patients with known hypersensitivity to any of the components of the PEGylated AuroShell suspension (polyethylene glycol, gold)

Prior known hypersensitivity to any of the excipients of alpelisib

Known hypersensitivity to immunoglobulins or to any other component of the IP formulation

Participants who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil) or to nab-paclitaxel and any of the excipients

Known hypersensitivity to thalidomide or lenalidomide

Known hypersensitivity to Velcade, boron, or mannitol

Have known hypersensitivity to platinum compounds or gemcitabine.

Patients with a known hypersensitivity to tacrolimus, methotrexate (Arm A or C) or MMF (Arm B or D)

Known history, or suspected hypersensitivity to any excipients.

History of known hypersensitivity to cetuximab, docetaxel or similar agents

Known hypersensitivity to the metal in the electrodes (stainless steel 304 L) that cannot be medically managed

Known hypersensitivity to orteronel or to orteronel excipients, which are listed by formulation in the Investigator Brochure

Known or suspected hypersensitivity to 5-azacitidine or mannitol

Part B only: Hypersensitivity to study drugs given in combination with LY3023414

Known hypersensitivity to any of the components of the study drugs

Known hypersensitivity to methotrexate

No known hypersensitivity to trastuzumab

Any known hypersensitivity to bevacizumab, erlotinib or other excipients of these drugs

Patients with a known hypersensitivity to treosulfan and/or fludarabine

Known hypersensitivity to any of the components of M7824 or eribulin.

Known hypersensitivity to thalidomide.

EXCLUSION - PARTICIPANT: Participants with a history of hypersensitivity reactions to study agent or their excipients.

Has a history of hypersensitivity to durvalumab or tremelimumab excipient

Hypersensitivity to IV contrast; not suitable for pre-medication

Previously known hypersensitivity to any of the agents used in this study; known sensitivity to melphalan

Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

Known hypersensitivity to bortezomib, ixazomib, dexamethasone, or ONC201

History of hypersensitivity to durvalumab, tremelimumab or any excipient.

Known hypersensitivity to any of the study drugs

The patient has known hypersensitivity to gelatin or lactose monohydrate

Proven hypersensitivity to statins

Known severe hypersensitivity to gemcitabine

Subjects with a known hypersensitivity to olaparib or any of the excipients of the product.

Known hypersensitivity to any of the components of LMB-100 and/or SEL-110

Known allergies, hypersensitivity or intolerance to apalutamide, abiraterone acetate, prednisone, or GNRH agonist or GNRH antagonist

History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib

Participants must not have hypersensitivity to nivolumab, urelumab, cabiralizumab or any of their excipients

History of hypersensitivity to cyclophosphamide, fludarabine, dimethyl sulfoxide (DMSO) or IL-2

Known hypersensitivity to any of the study drugs

Known hypersensitivity to any of the study drugs or analogs

Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] CTCAE v5.0 grade >= 3)

Has severe hypersensitivity (?Grade 3) to any study therapies including any excipients

Hypersensitivity to Ipilimumab and/or nivolumab or any of its excipients

Known hypersensitivity to gemcitabine (or other drug excipients) or chemically related drugs.

Known hypersensitivity to the device constituent or TARIS Inserter materials.

Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product

Known hypersensitivity/intolerance to capecitabine, infusional 5-flurouracil, or bevacizumab

Subject has known sensitivity and immediate hypersensitivity to any components of AMG 119 or conditioning regimen (cyclophosphamide and fludarabine).

Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients

History of severe hypersensitivity reactions to components of the cobimetinib, atezolizumab, or pembrolizumab formulations

Known intolerance or hypersensitivity to any of the products used in this study or their excipients.

Known hypersensitivity to any component of study drug including potential subjects with a history of major immunologic reaction to any IgG-containing agent

History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agents

Subjects with known hypersensitivity to study drugs or their excipients

Known hypersensitivity to nintedanib, nivolumab, ipilimumab, peanut or soy or any other trial drug, or their excipients

Previous hypersensitivity to rapamycin or rapamycin derivatives

Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds

Hypersensitivity (not including renal dysfunction or eye disorder) to CDV or to BCV or its formulation excipients

Patient has a known history of hypersensitivity to defibrotide or any of the excipients.

Carotid sinus hypersensitivity syndrome.

History of clinical hypersensitivity to the immunotherapy proposed for combination treatment.

History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid

Known hypersensitivity to any of the components of cabozantinib or nivolumab

A history of sun hypersensitivity or photosensitive dermatitis.

Participants with prior use of pirfenidone or known hypersensitivity to any of the components of study treatment will be excluded from the study

Severe hypersensitivity reactions to monoclonal antibodies, known hypersensitivity to the investigational medicinal products or to one or more of the excipients, autoimmune diseases (inflammatory bowel diseases, interstitial lung disease, or pulmonary fibrosis), and live vaccines within 28 days prior to study entry.

Hypersensitivity to ipilimumab or nivolumab or any of their excipients

Known hypersensitivity to immunoglobulins or to any other component of the IP formulation

History of hypersensitivity to IP or comparator agents

Known hypersensitivity to cetuximab or other EGFR antibody

Patients with a known hypersensitivity to the olaparib, carboplatin or cabazitaxel.

History of infusion-related reactions and/or hypersensitivity to trastuzumab, (ado-)trastuzumab emtansine;

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to Vicinium or its components

Has known hypersensitivity to baker's yeast

Previously known hypersensitivity to any of the agents used in this study; known sensitivity to busulfan or fludarabine

Hypersensitivity to nivolumab, ipilimumab, or any of its excipients

Known prior severe hypersensitivity to investigational product(s) or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v 4.03 grade >= 3).

History of severe hypersensitivity to nivolumab, cyclophosphamide, fludarabine, interleukin-2, or any excipient

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to thyrotropin alpha (Thyrogen)

Patients must not have a known hypersensitivity to the components of niraparib or the excipients

History of hypersensitivity to the combination of durvalumab and tremelimumab.

Hypersensitivity to nivolumab or ipilimumab or any of its excipients

Patients with known hypersensitivity to perflutren

History of hypersensitivity to durvalumab or any excipient

Known hypersensitivity to Avidin or AvidinOX (e.g. hen egg)

Known hypersensitivity to ST2210 (DOTA biotin) or any excipient.

Known prior hypersensitivity to the investigational product or any component formulations, including known severe hypersensitivity reactions to monoclonal antibodies

Known hypersensitivity to pirfenidone, carboplatin, pemetrexed or paclitaxel

(Bevacizumab-related exclusion) Known hypersensitivity to any component of bevacizumab

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to durvalumab or any excipient

Prior history of hypersensitivity to gemcitabine.

History of hypersensitivity to durvalumab or tremelimumab or any excipient

History of hypersensitivity to the combination or comparator agent (if applicable)

Patient with documented hypersensitivity to any of the components of the therapy program

Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid

FOR ALL PHASES (Ib AND II): Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation

Patients with known prior hypersensitivity reaction to any of the study drugs

Hypersensitivity to durvalumab or tremelimumab, or any excipients on the formulation

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to tremelimumab or any excipient

History of hypersensitivity to the combination or comparator agent

Known hypersensitivity to any of the study drugs

Documented hypersensitivity to bumetanide or sulfonamides

Has hypersensitivity to nivolumab or any other drug used in this protocol

Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds

Known hypersensitivity to the components of study drugs, its analogs, or drugs of similar chemical or biologic composition.

Known or suspected intolerance or hypersensitivity to IT-141 or any of the stated ingredients.

Patients with known hypersensitivity to 5-azacitdine or MK3475 or any of their excipients

Known hypersensitivity to any of the excipients of ribociclib or bicalutamide.

Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

History of hypersensitivity to durvalumab, tremelimumab, SGI-110, or any excipient

Known hypersensitivity to study drugs;

Known hypersensitivity to one or more of the study agents

Subject has known severe allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to the latest version of the Investigator Brochure), or known sensitivity to mammalian-derived products

History of clinical hypersensitivity to GM-CSF, Interferon-alpha-2b (Merck), yeast, beef, or to any components used in the preparation of the experimental vaccine.

Only for subjects enrolled in Arm 1 - Neratinib and everolimus: history of hypersensitivity to everolimus.

Known hypersensitivity to any of the excipients of ribociclib (LEE-011)

Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 grade >= 3)

Subjects with known hypersensitivity to study drugs or their excipients

Known hypersensitivity to olaparib or any of the excipients of the product

History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid

Known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients

Known hypersensitivity to pomalidomide, dexamethasone, or any excipients in elotuzumab, formulation, or recombinant protein

History of hypersensitivity to durvalumab, tremelimumab, or any excipient.

Known hypersensitivity to an component of bevacizumab

Known hypersensitivity to anetumab ravtansine, study drug classes or excipients in the formulation

Known hypersensitivity or intolerance to any of the agents under investigation

Known hypersensitivity to any of the study agents used

Have known hypersensitivity to the active substance or to an excipient of the study treatments.

Known hypersensitivity to any component of the nivolumab or ipilimumab product

History of severe hypersensitivity reactions to paclitaxel or any of its excipients.

Patient has a known hypersensitivity to any of the excipients of ribociclib, aromatase inhibitors (such as letrozole) or fulvestrant

History of hypersensitivity to durvalumab (MEDI4736), tremelimumab, or any excipient

Known or suspected hypersensitivity to azacitidine or mannitol

Hypersensitivity to nivolumab or lenalidomide or any of their excipients

Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure), or known sensitivity to mammalian-derived products

Known hypersensitivity to any study drug used in this trial

Hypersensitivity to ruxolitinib or any of its excipients

Allergic reaction/hypersensitivity to thalidomide or to the excipients contained in the formulation of durvalumab

Known hypersensitivity to any of the excipients of ribociclib or doxorubicin

Known hypersensitivity to brentuximab vedotin components

Known severe (grade >= 3 NCI-CTCAE version [v]4.03) hypersensitivity reactions to monoclonal antibodies, including hypersensitivity to the investigational agent or any component in its formulations, or history of anaphylaxis

Known hypersensitivity to any of the study drugs or analogs

Patients with a known history of hypersensitivity to lomustine, dacarbazine, or any components of lomustine

Known hypersensitivity to afatinib or its excipients

History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor®, or history of hypersensitivity type reaction to polysorbate 80 or other components of the formulation of Oraxol

Known hypersensitivity to immunoglobulins or any other component of the study drug

Patient has known hypersensitivity to the components of the study drugs or any analogs

History of hypersensitivity to durvalumab, tremelimumab, olaparib or, any excipient

Patient has known hypersensitivity to the components of the study drugs or their analogs

Known hypersensitivity to deferasirox

Known hypersensitivity to any component of the investigational product

Known hypersensitivity to azacitidine or mannitol

Known hypersensitivity to any study drug

History of hypersensitivity to AZD1775, irinotecan, or any excipients of these agents

Known hypersensitivity to nintedanib, gemcitabine and nab-Paclitaxel, peanut or soy or any other trial drug, their excipients

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to cyclophosphamide, fludarabine or IL-2.

Known hypersensitivity to either study drug (umbralisib or ibrutinib)

Known hypersensitivity to S-1 or its metabolites (eg, 5-FU);

Prior hypersensitivity to bevacizumab or toxicity requiring discontinuation of bevacizumab

History of hypersensitivity to durvalumab or any excipient

Known hypersensitivity to GT0918 or its excipients.

Known hypersensitivity to any excipient contained in the brentuximab formulation

Known hypersensitivity to the study drugs or the drugs with similar chemical structures

Known hypersensitivity to any of the components of LMB-100

Participants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxel

Known hypersensitivity to any of the components of LMB-100

Participants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxel

Known hypersensitivity to one or more of the study agents

Patients with a history of hypersensitivity to bosutinib or axitinib

History of any serious adverse reaction or hypersensitivity to cytarabine, unless reaction is deemed irrelevant to the study by the Investigator and Medical Monitor

Previously known hypersensitivity to any of the agents used in this study

Subject has a known allergic/hypersensitivity to investigational components or excipients (doxorubicin, trehalose, monoclonal antibody therapy, penicillin class of antibiotics, gentamicin (or other aminoglycosides), or ciprofloxacin hydrochloride (or other quinolones)).

History of hypersensitivity to osimertinib (or drugs with a similar chemical structure or class to osimertinib) or any excipients of these agents

Known hypersensitivity to the trial drugs (volasertib and romidepsin)

Patient has hypersensitivity to brentuximab vedotin

Known or possible hypersensitivity to palbociclib, fulvestrant, goserelin (if applicable) or to any of their excipients

Known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to paclitaxel or carboplatin or their excipients

Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its excipients

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to the combination or comparator agent

Known hypersensitivity to letrozole or fulvestrant, or any of its excipients, or to any palbociclib excipients

Patients with known history of hypersensitivity to paclitaxel that did not resolve with pre-medication

Known hypersensitivity to any component of ado-trastuzumab emtansine

Known hypersensitivity to the components of study drugs, its analogs, or drugs of similar chemical or biologic composition

Known hypersensitivity to exemestane or its excipients

Known hypersensitivity to nintedanib, any other trial drug, or their excipients

History of hypersensitivity to hydrogel.

Known hypersensitivity to lenalidomide, dexamethasone, any excipients in the elotuzumab formulation (sodium citrate, citric acid, sucrose and polysorbate 80) or recombinant protein

Previously known hypersensitivity to any of the agents used in this study

Known hypersensitivity to any study drug component.

Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation

Patient has known hypersensitivity to any of the excipients of ribociclib

History of hypersensitivity to MEDI4736 or any excipient

History of hypersensitivity to tremelimumab or the combination of MEDI4736 + tremelimumab

History of hypersensitivity of lenalidomide or thalidomide

Known hypersensitivity reactions to any of the components of Sym004

History of hypersensitivity to durvalumab or tremelimumab or any excipient

Hypersensitivity to simvastatin or ezetimibe.

Known hypersensitivity to any of the components of atezolizumab or nab-paclitaxel

Patients with known hypersensitivity to taxanes or platinums are to be excluded

Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

Known or possible hypersensitivity to palbociclib (CTCAE version [V] 4.03)

Patients with known hypersensitivity to the components of the study drugs or their analogs

A history of hypersensitivity to selumetinib, or any excipient agents (e.g. Captisol or TPGS- a water soluble form of Vitamin E)

Patients with a known hypersensitivity to olaparib or tremelimumab

Known sensitivity to kanamycin and other aminoglycosides; patients with known hypersensitivity to kanamycin or any other aminoglycoside antibiotic will be excluded

No known hypersensitivity to rat monoclonal antibodies

Known intolerance or hypersensitivity to rapamycin analogs (e.g. sirolimus, temsirolimus)

Has known hypersensitivity to MK-3475 (pembrolizumab) or any of its incipients

Patients with a known hypersensitivity to gemcitabine (Arm B only)

Patients with hypersensitivity to docetaxel or polysorbate 80 (Arm A only)

Known HER2 status

Subject has a known hypersensitivity to pembrolizumab or any of its ingredients

Known hypersensitivity to any component of the product (lenvatinib or ingredients).

History of hypersensitivity to lenalidomide (Part B only)

Known hypersensitivity to any of the components of talazoparib

Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5–fluorouracil

History of hypersensitivity to any component of the formulation

Known hypersensitivity to afatinib or the excipients of any of the trial drugs

Has known hypersensitivity to pembrolizumab (MK-3475) or its formulation

Known hypersensitivity to S-equol or any of its excipients

Patients with a known hypersensitivity to interferon-alpha

Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

Known hypersensitivity to any of the study drugs

History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride (HCL) or the components of doxil, paclitaxel, or carboplatin

Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

History of hypersensitivity to MEDI4736 or any excipient.

Known hypersensitivity to 5-FU injection, poor nutritional state, known dipyrimidine dehydrogenase deficiency, or taking sorivudine (such as Usevir, Bravavir, etc.)

History of hypersensitivity to active or inactive excipients of any component of treatment

Known hypersensitivity or infusion reaction to cisplatin and gemcitabine

Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

History of hypersensitivity to paclitaxel

Patients with documented hypersensitivity to any components of the study program

Subjects with history of hypersensitivity to azoles

Known hypersensitivity to any component of bevacizumab

Patient with documented hypersensitivity to any of the components of the chemotherapy program

Patients with a known hypersensitivity to BKM120 or to its excipients

Patients with known hypersensitivity to any of the components of PFK-158.

Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

History of hypersensitivity to mannitol

Known hypersensitivity to thalidomide or lenalidomide

Patients with known hypersensitivity to gemcitabine or docetaxel

Patients with known hypersensitivity to pegfilgrastim and filgrastim

Known hypersensitivity to thalidomide, lenalidomide or ipilimumab

Known hypersensitivity to any component of Avastin

Known hypersensitivity to one or more of the study agents

Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab

Known hypersensitivity to bevacizumab or any of its excipients or any other study drug

Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds

Hypersensitivity of TZD

Known hypersensitivity or other serious adverse reaction to any azole antifungal therapy or to any other ingredient of the study medication used.

Subjects must not have a known history of hypersensitivity to mannitol

Known hypersensitivity to thalidomide

Known or suspected hypersensitivity to ruxolitinib.

Must not have a known or suspected hypersensitivity to azacitidine, mannitol, or compounds of similar composition to azacitidine

Known hypersensitivity or desquamating rash to either thalidomide or lenalidomide

Patients with known hypersensitivity to any excipient contained in the drug formulation.

Known hypersensitivity to 5AC or GM-CSF

Previously known hypersensitivity to any of the agents used in this study

Patient has known hypersensitivity to the components of study drug or its analogs

Any history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80

Prior use of gossypol or AT-101, or known hypersensitivity to gossypol or AT-101

Patient with documented hypersensitivity to any of the component medications

Hypersensitivity to mithramycin

History of hypersensitivity to sirolimus, temsirolimus, everolimus

History of hypersensitivity to any component of the formulation

Patients with known hypersensitivity to the components of study drug or its analogs

History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation

History of hypersensitivity to vemurafenib

History of hypersensitivity to sorafenib for vemurafenib/sorafenib arm

History of hypersensitivity to crizotinib for vemurafenib/crizotinib arm

History of hypersensitivity to any component of the formulation

Patient with documented hypersensitivity to any of the components of the chemotherapy program

Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients

Known hypersensitivity to thalidomide

Have known allergies, hypersensitivity, or intolerance to abiraterone acetate, apalutamide or prednisone or their excipients

Patients with history of hypersensitivity to conductive hydrogel are not eligible

History of hypersensitivity active or inactive excipients of AZD9291 (osimertinib) or drugs with a similar chemical structure or class to AZD9291 (osimertinib)

Hypersensitivity to decitabine, guadecitabine, or any of their excipients.

Known hypersensitivity to enzalutamide or any of its components.

Patients with a history of or known hypersensitivity to melphalan or the components of the Melphalan/HDS system.

Known hypersensitivity to any component of axitinib or prior use of axitinib

Patients who are (MVF-HER-2[266-296] and MVF-HER-2 [597-626]) immediate hypersensitivity skin test positive

Patients with a known hypersensitivity to any of the study agents

Prior history of hypersensitivity reactions to oxaliplatin, bevacizumab, fluorouracil (5-FU) or capecitabine

Known hypersensitivity to thalidomide or lenalidomide

Known severe hypersensitivity to trastuzumab (excluding mild to moderate infusion reactions that are easily managed and do not recur)

Known hypersensitivity to any component of topotecan or doxorubicin or other required drugs in the study

Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Please refer to Study Appendix O for a complete list of Polysorbate 80 containing drugs.

Known hypersensitivity to thalidomide.

Known hypersensitivity to any component of the study medication(s).

Known allergies, hypersensitivity, or intolerance to the IP or its excipients

Has hypersensitivity to eribulin or any of the excipients

Allergies, hypersensitivity, or intolerance to niraparib or the corresponding excipients

Known hypersensitivity to ASN007 or its excipients;

Subjects who have a hypersensitivity to aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)

Patients who have received prior treatment with a PI3K inhibitor or have known hypersensitivity to Gedatolisib or its excipients

Known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80

History of hypersensitivity to durvalumab or any excipient.

hypersensitivity to the active substance or to any of the excipients of study drug;

Patients with known hypersensitivity to any of the components of MCLA-117 or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;

Known hypersensitivity to any of the excipients of INC280

Subject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide

Have a known sensitivity to any of the components of Andes-1537

Have a history of hypersensitivity reaction to any of the components of Temozolomide

Have a history of hypersensitivity to dacarbazine (DTIC)

Allergies or hypersensitivity to murine, chimeric, human or humanised proteins

Has known hypersensitivity to TAS-119 or its components.

Has known hypersensitivity to Cremophor® EL, paclitaxel or its components.

History or presence of hypersensitivity or idiosyncratic reaction to deferiprone or deferoxamine;

Patients previously treated with docetaxel for NSCLC or with known severe hypersensitivity to taxane therapies.

Patients with a known hypersensitivity to BKM120 or to its excipients

Patient with hypersensitivity to bortezomib, boron or dexamethasone

History of hypersensitivity to a taxane

Hypersensitivity to fluphenazine or other phenothiazines

Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation

Hypersensitivity to AQ4N or to any ingredients contained in the drug formulation.

Hypersensitivity to temozolomide or to any ingredients contained in the drug formulation and dacarbazine (DTIC).

Subjects to receive ofatumumab: hypersensitivity to ofatumumab or its excipients.

Known hypersensitivity to MMB, its metabolites, or formulation excipients

Steroids as premedication for hypersensitivity reactions are permitted;

Patients with a known hypersensitivity to olaparib or any of the excipients of the product.

Hypersensitivity to any reagents used in the study.

Known hypersensitivity to any study drug

Patients with a known hypersensitivity to olaparib or any of the excipients of the product

Patients with a known hypersensitivity to the testosterone cypionate or any of the excipients of the product

Known hypersensitivity to any of the components of talazoparib

Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC).

Known hypersensitivity to irinotecan or its excipients.

History of hypersensitivity to cyclophosphamide, fludarabine or IL-2

Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients

Known hypersensitivity to enzalutamide

Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material

Known or possible hypersensitivity to fulvestrant, or palbociclib or any of their excipients.

Patients with hypersensitivity to mannitol are not eligible; patients who have known hypersensitivity to peanut or soya, any other trial drug, or their excipients, or to contrast media are not eligible

Known hypersensitivity to the components of study drugs or analogs of study drugs

Known hypersensitivity to any of the study agents

Known hypersensitivity to fluorouracil (5-FU), oxaliplatin, or other platinum agents

Known hypersensitivity to nab-paclitaxel or any of its excipients

Patients with a known hypersensitivity to olaparib or any of the excipients of the product.

History of hypersensitivity to durvalumab, guadecitabine (SGI-110) or any excipient

Subject has known allergies, hypersensitivity, or intolerance to boron or mannitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products

Patient has a known hypersensitivity to any of the excipients of BYL719 and/or enzalutamide.

Hypersensitivity to acetazolamide or sulfonamides

Patient with documented hypersensitivity to any of the components of the chemotherapy program

Has known serious hypersensitivity reactions to peg-interferon alfa-2b or interferon alfa-2b

Known hypersensitivity or intolerance to any of the agents under investigation

Known hypersensitivity to any of the components of PRI?724, fluorouracil (5?FU), oxaliplatin or bevacizumab

Patient has a known hypersensitivity to any of the excipients of BYL719 (alpelisib)

Known hypersensitivity to arsenic trioxide

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to the combination or comparator agent (If applicable)

Known hypersensitivity to any components of study drugs

Have a known hypersensitivity to any of the components of AG-120, matched placebo, or azacitidine.

Known hypersensitivity to Cremophor®-based agents

patient has known hypersensitivity to alpelisib, fulvestrant or letrozole

Known hypersensitivity reaction to GM-CSF

Have known hypersensitivity to the active substance or to an excipient for a study treatment.

Hypersensitivity to decitabine, guadecitabine, or any of their excipients.

A known hypersensitivity to abiraterone acetate, apalutamide, and prednisone and/or any of their excipients

Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug or vehicle formulation for margetuximab or pembrolizumab.

Patients with a prior hypersensitivity reaction to sargramostim

Prior allergic reaction or hypersensitivity to cetuximab or MEDI4736 (durvalumab) or any of study drug excipients

The subject has a history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to dacarbazine (DTIC)

Patient has hypersensitivity to bortezomib, boron, or mannitol

Patients with a known hypersensitivity to gemtuzumab ozogamicin or its parts: recombinant humanized anti-CD33 monoclonal (hP67.6) antibody, calicheamicin derivatives or other ingredients

TREATMENT: Patients with known hypersensitivity reaction to dacarbazine are ineligible to receive temozolomide

Known hypersensitivity to any of the components of tazemetostat

Known prior or suspected hypersensitivity to study drugs or any component in their formulations

History of erythema multiforme or severe hypersensitivity to prior IMiD’s such as thalidomide and lenalidomide

History of hypersensitivity to durvalumab or any excipient

Hypersensitivity to mithramycin

Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation

Known hypersensitivity to cetuximab or other EGFR antibody

Known hypersensitivity to inactive ingredient of bevacizumab

Known hypersensitivity to inactive ingredient of TPI 287

Known documented or suspected hypersensitivity to the components of the study drug(s) or analogs

Patients must not have a history of hypersensitivity to active or inactive excipients of AZD4547 or drugs with a similar chemical structure or class to AZD4547

Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other antigen

Known hypersensitivity to ledipasvir, sofosbuvir, or formulation excipients

Patient has a known hypersensitivity to any of the excipients of buparlisib

Patient has a known hypersensitivity to ribociclib or excipients of tamoxifen

Patient has known hypersensitivity to any of the excipients of ribociclib

Known hypersensitivity to any of the study agents used

Subject has a known hypersensitivity to any of the excipients of nab-paclitaxel or BYL719/alpelisib

History of hypersensitivity to dacarbazine

Hypersensitivity to trial medications (everolimus)

Known hypersensitivity to any of the following: bortezomib, boron, mannitol

Patients with hypersensitivity to excipients of the study drug are not eligible

Hypersensitivity to any of the study medications

Patients with known hypersensitivity to temozolomide or dacarbazine are not eligible

Known hypersensitivity to any of the study drugs or any of the ingredients or excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl alcohol

Known hypersensitivity to afatinib, dasatinib, or the excipients of any of the trial drugs

With known hypersensitivity to treosulfan or fludarabine (fludarabine phosphate)

Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients

Patients with a known hypersensitivity to olaparib or any of the excipients of the product; patients with known hypersensitivity cetuximab or any of the excipients of the product

Patients who have hypersensitivity to sitagliptin

Patients will be excluded if there is any history of allergic reaction(s) attributed to compounds of similar composition to temsirolimus, sorafenib, their metabolites, or any component of their formulation (including excipients and polysorbate 80); this includes hypersensitivity to macrolide antibiotics due to potential for cross-reactivity with temsirolimus

Patients with previous hypersensitivity reaction to camptothecins are excluded

Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C

Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C

Documented hypersensitivity to clobetasol

Patients with a known hypersensitivity to RAD001(everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients

Known hypersensitivity to oxaliplatin, other platinum-containing compounds

Must not have known hypersensitivity to 4-aminoquinoline compound

Patients with a known hypersensitivity to BKM120, RAD001 (including other rapalogs) or their excipient

Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients

Patients with known hypersensitivity to anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate

Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component

Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component

Previous history of hypersensitivity to bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogs

Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol

Known hypersensitivity to any component of bevacizumab or to nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation)

Hypersensitivity to interferon-alpha (IFN-alpha)

Hypersensitivity to interferon alfa

Suspected hypersensitivity to IFN alfa2b

Patient must not be known to have hypersensitivity to TAK-700, to TAK-700 metabolites, to bicalutamide, or to LHRH agonist

Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (Cremophor).

Subject with known or suspected hypersensitivity to seviteronel, or any components of the formulation

Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.

Contraindications or history of allergic reaction to lapatinib or to capecitabine, known dihydropyrimidine dehydrogenase deficiency, or known hypersensitivity of 5-fluorouracil

Patients with known Aspirin-Hypersensitivity triad (asthma, allergic rhinitis, ASA hypersensitivity).

Patients with known hypersensitivity to celecoxib or other NSAIDs, aspirin or sulfonamides.

Known hypersensitivity to any of the components of talazoparib

Has a history of severe hypersensitivity reaction (e.g. generalized rash/erythema, hypotension, bronchospasm, angioedema or anaphylaxis) to pembrolizumab, gemcitabine, carboplatin, or cisplatin or their analogs and/or to any of their excipients.

Patients with a history of hypersensitivity to sirolimus or any component of the formulation.

hypersensitivity to trastuzumab, murine proteins, fulvestrant, or to any of the excipients

History of intolerance or hypersensitivity to study drug

Hypersensitivity to erlotinib or alectinib or to any of the excipients.

Subject has a history of hypersensitivity to porcine derived gelatin or collagen.

Subject has a history of hypersensitivity to microbial Transglutaminase.

Known history of immunogenicity or hypersensitivity to a CD25 antibody.

Known hypersensitivity to any of the components of RO6958688 and/or obinutuzumab

Hypersensitivity to ASTX660, excipients of the drug product, or other components of the study treatment regimen.

Known hypersensitivity to any component of the investigational products; known hypersensitivity to salicylates; known hypersensitivity to aspartame-containing products for patients with phenylketonuria; known allergies to any of the medications or components of medications used in the trial

Subject has a known hypersensitivity to any of the excipients of nivolumab, cisplatin or romidepsin

Known hypersensitivity to any study drug component

Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs.

Known hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM 1 or irinotecan or any of its components if enrolled on ARM 2

Known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib/placebo excipients or to endocrine treatments.

Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the drug formulation.

Patients must not have any known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients

Known hypersensitivity to any excipients of tesevatinib.

Known or suspected hypersensitivity to the excipients contained in the formulation of durvalumab, lenalidomide, or dexamethasone

Known hypersensitivity to any of the GTx-024 components or subjects previously received treatment with SARM

Known intolerance/hypersensitivity to IMiDs, dexamethasone, boron or mannitol, sucrose, histidine or polysorbate 80.

Participants who had a prior exposure to trabectedin or hypersensitivity to any of the excipients will not be excluded from receiving single-agent Doxil

Known allergies, hypersensitivity, or intolerance to Doxil, dexamethasone, or their excipients

Known or suspected hypersensitivity to azacitidine or mannitol

Patients with a history of severe hypersensitivity reaction to Taxotere (docetaxel) or other drugs formulated with polysorbate 80

Has known hypersensitivity to any of the components of IP.

Have a known hypersensitivity to investigator's choice of standard of care (gemcitabine or capecitabine).

Patients must not have known hypersensitivity to irinotecan, fluorouracil, or leucovorin

Known or suspected hypersensitivity to azacitidine, mannitol, or durvalumab, its constituents, or to any other humanized monoclonal antibody.

Patient has a known hypersensitivity to any of the excipients of ribociclib

Has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, POM, or dex

Known hypersensitivity reaction to the GM-CSF adjuvant; Any known contra-indication to GM-CSF or Cyclophosphamide treatment;

Hypersensitivity or prior treatment with obinutuzumab

Known hypersensitivity to the study treatment or any of its ingredients.

History of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulation

Have a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.

Known history of immunogenicity or hypersensitivity to a CD19 antibody.

Known hypersensitivity to study drug, study drug classes or excipients of the formulation.

No known hypersensitivity to gemcitabine or nab-paclitaxel

Hypersensitivity to thalidomide, lenalidomide, pomalidomide, or dexamethasone

Intolerance or hypersensitivity to octreotide

Known or suspected hypersensitivity to azacitidine or mannitol or any other ingredient used in the manufacture of oral azacitidine (see the current azacitidine IB).

Known hypersensitivity to 5-fluorouracil/leucovorin

Known hypersensitivity to oxaliplatin or other platinum containing compounds

Known hypersensitivity to irinotecan

Have known or suspected hypersensitivity to azacitidine or any other ingredient used in the manufacturing of Azacitidine.

Known hypersensitivity to the components of the study therapy or its analogs.

Known hypersensitivity to the components of the study therapy. (Please reference Section 1, Formulation of EC1169 and EC0652, in the respective Pharmacy Manuals)

Known hypersensitivity to momelotinib, its metabolites, or formulation excipients

Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or lenalidomide

Hypersensitivity to the active ingredient or any of the excipients including lactose.

Known hypersensitivity to thalidomide

For MM-2 cohort only: Hypersensitivity (eg, Rash Grade 3 or 4) to thalidomide, lenalidomide, or dexamethasone (MM-2b).

Patient has hypersensitivity to bortezomib, boron or mannitol

History of severe hypersensitivity reaction to study treatments or their excipients.

Known hypersensitivity to any of plitidepsin's formulation components

Known allergies, hypersensitivity, or intolerance to talacotuzumab and daratumumab or their excipients

Hypersensitivity to IMiDs (thalidomide or lenalidomide) defined as any hypersensitivity reaction leading to stop IMiDs within the 2 first cycles or toxicity, which does meet intolerance definition.

Known hypersensitivity to the study drugs (GS 5829, fulvestrant or exemestane), the metabolites, or formulation excipients

Known hypersensitivity to any of the study drugs or excipients

Prior treatment with or hypersensitivity to study drug or related compounds

Known hypersensitivity to any component of lenvatinib or midazolam.

Known hypersensitivity to mannitol.

Patient has a known hypersensitivity to Ribociclib or any of its excipients.

Known hypersensitivity to bicalutamide.

Known hypersensitivity to any of the study drugs or excipients

Known hypersensitivity to a component of protocol therapy

Patients with a known hypersensitivity to any excipient contained in the drug

Have known intolerance to the Test Article (ie, documented hypersensitivity AE to prior monoclonal antibody therapy, or to amatuximab or any of its excipients)

Known hypersensitivity to any of the components of talazoparib

Known serious reactions or hypersensitivity to any components of the UV1 vaccine or similar peptide based vaccines

Known hypersensitivity to GM-CSF

Has a known hypersensitivity to azacitidine or mannitol

Patients with known hypersensitivity to any TZD oral agents are not eligible

Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

Known hypersensitivity to the trial drugs or to their excipients

History of hypersensitivity to LCI699 or to drugs of similar chemical classes.

Hypersensitivity to 5FU (fluorouracil), oxaliplatin (or other platinum agents), irinotecan (irinotecan hydrochloride) (or to their excipients)

Known hypersensitivity to afatinib or letrozole or the excipients of any of the trial drugs.

History of hypersensitivity to any of the additives in the alectinib and crizotinib drug formulation

Previously known hypersensitivity to any of the agents used in this study

Known hypersensitivity to any study drug component including thapsigargin derivatives, polysorbate 20, or propylene glycol

Known hypersensitivity to one or more of the study agents

Known hypersensitivity to any study drug

Known hypersensitivity to any of the components of talazoparib

Known hypersensitivity to the components of niraparib

Patients with a known hypersensitivity to any excipient contained in the drug formulation

Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol

History of hypersensitivity to anakinra.

History of hypersensitivity to denosumab.

History of hypersensitivity to everolimus.

History of hypersensitivity to any component of the formulation.

Patients must not have hypersensitivity to bortezomib, boron or mannitol

Subject has a known hypersensitivity to monoclonal antibodies or to agents of similar biologic composition as IMC-CS4.

Previously known hypersensitivity to any of the agents used in this study

Patients with a known hypersensitivity to any component of bevacizumab are not eligible for this trial

Have a history of hypersensitivity to any study drugs or their excipients, or intolerance to hydration due to preexisting pulmonary or cardiac impairment, or intolerance to opioid pain medications, or a history of severe hypersensitivity to any other antigen.

Known prior clinically relevant hypersensitivity reaction to thalidomide, including the development of erythema nodosum if characterized by a desquamating rash

Patients with known hypersensitivity to any of the components of an investigational treatment will be excluded from participation in the corresponding arm but are eligible for participation in other study arm; Patients that have a history of hypersensitivity to rapamycin derivatives will be excluded from participation in the everolimus arm

Steroids for the treatment of hypersensitivity or transfusion reactions, nausea/vomiting or pain

Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole

Patients with known hypersensitivity to any oligodeoxynucleotide.

Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients

Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGA271 or pembrolizumab.

Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

Known intolerance or hypersensitivity to progesterone or its excipients

History of hypersensitivity to castor oil

Patients with a history of severe hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80

Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency

Known hypersensitivity to capecitabine, fluorouracil, or any component of the formulation

Patients with a known hypersensitivity to ribociclib or everolimus or to its excipients.

Known allergies, hypersensitivity, or intolerance to any form of heparin or azacitidine

History of hypersensitivity to durvalumab or any excipient

Prior treatment with nintedanib (BIBF1120); known hypersensitivity to nintedanib, peanut or soya or any other trial drug, their excipients or to contrast media

History of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014

History of hypersensitivity to ibrutinib

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to TPIV200

Known hypersensitivity reaction to the GM-CSF adjuvant

Hypersensitivity to pegfilgrastim or Escherichia (E.) coli derived proteins

Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other Antigen.

Known hypersensitivity to ibrutinib or any component of the ibrutinib formulation

No known hypersensitivity to BIBF 1120, to its excipients or to contrast media

Known hypersensitivity to thalidomide or lenalidomide

Participant has a known or suspected hypersensitivity to azacitidine, mannitol, or any other ingredient used in the manufacture of CC-486 (see the Azacitidine IB).

Known hypersensitivity to murine or chimeric antibodies or proteins

Known hypersensitivity to any of the study drugs

Known hypersensitivity to enzalutamide or related compounds

Known prior severe allergic/hypersensitivity to the chemotherapy or any of the components of the study treatment

Known history of hypersensitivity to active or inactive excipients of HM61713 or drugs with a similar chemical structure of HM61713

Contraindication to any required concomitant drugs or supportive therapies including hypersensitivity to all anticoagulation and antiplatelet options or hypersensitivity to acyclovir or similar anti-viral drug

Patient has hypersensitivity to bortezomib, boron, or mannitol

Has known hypersensitivity to paclitaxel

Patient has a known hypersensitivity to LEE011 or any of its excipients

Has known hypersensitivity to fluorouracil (5FU), oxaliplatin, or other platinum agents.

Known hypersensitivity to acyclovir or similar anti-viral drug

History of hypersensitivity to any excipients in the investigational product.

Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation

Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study.

Known hypersensitivity to thalidomide

Known hypersensitivity to ibrutinib

No known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib excipients or to endocrine treatments.

Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

Patient has a known hypersensitivity to any of the excipients of BYL719

Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).

Subject has a known hypersensitivity to platinum compounds.

Known hypersensitivity to thalidomide or lenalidomide

Hypersensitivity to chlorambucil, obinutuzumab, or venetoclax or to any of the excipients

Known hypersensitivity to everolimus or bendamustine

Known hypersensitivity to trial drug

Known hypersensitivity to any of the study drugs

Patients with a known hypersensitivity to BKM120 or to its excipients

Patients with known hypersensitivity to olaparib, AZD5363, AZD2014 or any of their excipients; patients with a history of hypersensitivity to drugs with a similar chemical structure or class to olaparib, AZD5363, or AZD2014

History of severe hypersensitivity reaction (>= grade 3) to polysorbate 80 containing drugs

Known hypersensitivity to thalidomide or lenalidomide

Known hypersensitivity to any of the components of ipilimumab, bevacizumab, or nab-paclitaxel

Documented hypersensitivity to any of the drugs used in the protocol

Known hypersensitivity to any of the study drugs or excipients

Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).

Subject has a known hypersensitivity to platinum compounds.

Known intolerance or hypersensitivity to vitamin E, everolimus or to rapamycin derivatives

Have a known or suspected hypersensitivity to brigatinib or its excipients.

Subjects with known hypersensitivity to any of the components of AG-120.

Patients with a known hypersensitivity to BKM120 or its excipients

Patients with a history of grade >= 3 hypersensitivity reaction to trastuzumab, OR grade >= 1 with the most recent trastuzumab infusion before study entry, OR continued requirement for prolonged trastuzumab infusions to prevent hypersensitivity reactions are not eligible for participation

Have known allergies, hypersensitivity, or intolerance to AA or prednisone or their excipients

Known hypersensitivity to 5-fluorouracil/leucovorin

Known hypersensitivity to capecitabine

Known hypersensitivity to oxaliplatin or other platinum containing compounds

Known hypersensitivity to irinotecan

Known hypersensitivity to any component of bevacizumab

Known hypersensitivity to regorafenib

Subjects with hypersensitivity to study drugs or their excipients

Hypersensitivity to ofatumumab or its excipients

Known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies

Known hypersensitivity to any immunomodulatory drugs (IMiDs), including Grade 4 rash

Known hypersensitivity or intolerance to dexamethasone

Hypersensitivity to thalidomide, lenalidomide, or dexamethasone (such as Steven Johnson Syndrome). Hypersensitivity, such as rash, that can be medically managed is allowable

History of hypersensitivity to active or inactive excipients of olaparib or abiraterone or drugs with a similar chemical structure or class to olaparib or abiraterone.

Hypersensitivity to any of the study medications or any of the ingredients or excipients of these medications, including hypersensitivity to benzyl alcohol

Known hypersensitivity to acyclovir or similar anti-viral drug

Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients

Known hypersensitivity to pembrolizumab or another mAb.

Known hypersensitivity to both allopurinol and rasburicase

History of hypersensitivity to any compound in the tetracycline antibiotics group

Steroids for the treatment of hypersensitivity or transfusion reactions.

Known or suspected hypersensitivity to azacitidine or mannitol

Patients with a known hypersensitivity to olaparib or any of the excipients of the product.

Prior history of infusion reactions or hypersensitivity to any of the study drugs

Participants who have known hypersensitivity to any component of loperamide or budesonide

Hypersensitivity to previous lenalidomide or thalidomide

Have known allergies, hypersensitivity, or intolerance to enzalutamide or their excipients

Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients

Patients with a known hypersensitivity to pazopanib or topotecan or to their excipients

Subjects with known hypersensitivity to any of the components of AG-221.

Patients with a known hypersensitivity to any component of bevacizumab are not eligible for participation

Known hypersensitivity to RAD001 or other rapamycins (sirolimus, temsirolimus, deforolimus)

Patients with a known hypersensitivity to tacrolimus

Known hypersensitivity to bortezomib, boron, or mannitol

Patient with known hypersensitivity to any of the excipients of LDK378 (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

Patient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel or any known excipients of these drugs.

Patients with a known hypersensitivity to BKM120 or to its excipients, or hypersensitivity to cetuximab

Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients

Known anaphylactic or severe hypersensitivity to the study drugs or their analogs

Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients

History of intolerance, including Grade 3 to 4 infusion reaction or hypersensitivity to trastuzumab or murine proteins or any components of the product

Known hypersensitivity to thalidomide

Known allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone or degarelix

History of hypersensitivity to ipilimumab

History of hypersensitivity to lenalidomide

Known anaphylactic or severe hypersensitivity to dasatinib or crizotinib or their analogs

Known hypersensitivity to thalidomide, lenalidomide or rituximab; including the development of erythema nodosum if characterized by a desquamating rash while taking thalidomide

Known hypersensitivity to bortezomib, boron, or any of the other agents utilized in this protocol

Hypersensitivity to one of the trial drugs or the excipients.

Known hypersensitivity to Cremophor EL. However, participants are eligible if they have had a prior paclitaxel reaction, but subsequently tolerated the drug at rechallenge.

Known hypersensitivity to protein bound paclitaxel

Known hypersensitivity to mTOR inhibitors, e.g., sirolimus (rapamycin).

Known severe hypersensitivity to tadalafil or any of the excipients of this product

Hypersensitivity to thalidomide, lenalidomide or pomalidomide

Known or suspected hypersensitivity to the excipients contained in the study drug formulation.

Known hypersensitivity to thalidomide or lenalidomide (if applicable)

Patient has hypersensitivity to bortezomib, boron, or mannitol

Patients with known hypersensitivity to rapamycins

Known hypersensitivity to brentuximab vedotin, bendamustine, or mannitol

No known hypersensitivity to 4-aminoquinoline compound

No known prior hypersensitivity to carboplatin, paclitaxel, bevacizumab or hydroxychloroquine or any of their components

Patients with hypersensitivity to any tetracyclines

Known hypersensitivity to any components of the treatments

Any concern for hypersensitivity to pazopanib, gemcitabine or docetaxel

Patients with previous hypersensitivity reactions to the study drugs and components (ex: podophyllum and povidone).

Known hypersensitivity to thalidomide or lenalidomide.

Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD

Patients with a known hypersensitivity to everolimus (RAD001) or other rapamycins (sirolimus, temsirolimus) or to its excipients

Known anaphylactic or severe hypersensitivity to study drugs or their analogs

Known hypersensitivity to thalidomide or lenalidomide

Known or suspected hypersensitivity to 5-azacitidine, romidepsin, mannitol or other agents used in this study

No known hypersensitivity to ofatumumab, humanized antibodies or chemotherapy agents throughout the protocol

Known hypersensitivity to capecitabine, temozolomide, or any component of the formulation and or a known deficiency of dihydropyrimidine dehydrogenase

Known hypersensitivity to any component of bevacizumab

The patient has known hypersensitivity to bovine proteins

Hypersensitivity to one or more of the TL-118 active components

Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil

Hypersensitivity to propranolol, or beta-blockers

Known hypersensitivity to thalidomide

Known hypersensitivity to any component of bevacizumab

History of hypersensitivity reactions to any components of the treatment regimen

Patients with a known hypersensitivity to any excipient contained in the drug formulation

Known hypersensitivity to thalidomide.

Known hypersensitivity to any component of the trial agents

Known hypersensitivity to any component of the formulation

Any known hypersensitivity to ofatumumab or its components.

Hypersensitivity to acyclovir or similar anti-viral drug

Hypersensitivity to boron or mannitol, or compounds containing these components

Known hypersensitivity to cetuximab or other EGFR antibody

Patients with a history of severe hypersensitivity reaction to JEVTANA (cabazitaxel) or other drugs formulated with polysorbate 80

Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

Known hypersensitivity to any component of bevacizumab

Known hypersensitivity to any of the study agents used

Known hypersensitivity to thalidomide or lenalidomide.

Known hypersensitivity to any of the study agents

Patients with known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation that includes trehalose, sodium citrate, and polysorbate 80

Known hypersensitivity to any of the following: diphtheria toxoid, neomycin, polymyxin B, streptomycin, 2 phenoxyethanol, formaldehyde, aluminum hydroxide, yeast

Patient has known hypersensitivity to the components of study drug or its analogs

E 16. History of hypersensitivity to docetaxel, or polysorbate 80.

Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients

Patients with a known hypersensitivity to vinorelbine or to its excipients

Known hypersensitivity to any of the components of MM-302 or who have had hypersensitivity reactions to fully human monoclonal antibodies

Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation

Known hypersensitivity to fluoropyrimidines or cisplatin.

Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients

Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide long-acting release [LAR] formulations

History of hypersensitivity to sirolimus

History of hypersensitivity to vorinostat

History of hypersensitivity to hydroxychloroquine

History of hypersensitivity to any component of the formulation

Prior carboplatin or cisplatin hypersensitivity reaction

For Part C, have a known hypersensitivity to sorafenib or its excipients

Patient has known hypersensitivity to thalidomide

Known hypersensitivity to thalidomide

Known hypersensitivity to any component of bevacizumab

CARBOPLATIN ARM: hypersensitivity to carboplatin or any component of the formulation

PACLITAXEL ARM: hypersensitivity to paclitaxel or any component of the formulation

SORAFENIB ARM: history of hypersensitivity to sorafenib or any component of the formulation

Patient has hypersensitivity to bortezomib, boron or mannitol

Any history of adverse reaction or hypersensitivity to LDAC

Known hypersensitivity to thalidomide, lenalidomide, azacitidine, or mannitol

Known hypersensitivity to any component of bevacizumab

Known hypersensitivity to thalidomide

Known intolerance to either of the study drugs (or any of the excipients)

History of hypersensitivity to durvalumab, tremelimumab or any excipient

Known hypersensitivity to any components of pracinostat, azacitidine, or mannitol

Known history of hypersensitivity to aromatase-inhibitor drugs

Patients with known hypersensitivity to any oligodeoxynucleotide that cannot be adequately managed with appropriate prophylaxis; e.g. steroids.

Has a known hypersensitivity to the components of the study treatment or its analogs.

Prior treatment with or have known hypersensitivity to AL3818.

b. Indication B- LMS: Prior treatment with or have known hypersensitivity to dacarbazine.

c. Indication C - SS: Prior treatment with or have known hypersensitivity to dacarbazine.

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to tremelimumab

Known allergies, hypersensitivity, or intolerance to TRC253 or its excipients.

Has known hypersensitivity to baker's yeast

Known hypersensitivity to cyclophosphamide, its metabolites or any other components, or known urinary outflow obstruction.

Known hypersensitivity to any component of the investigational product (PVX-410, durvalumab, or any excipient)

Known intolerance to any of the study drugs (or any of the excipients)

Known hypersensitivity to any component of bevacizumab and osimertinib

History of hypersensitivity to gemcitabine

History of hypersensitivity to nab-paclitaxel or paclitaxel

Known hypersensitivity to sirolimus.

Known hypersensitivity to docetaxel, fluorouracil (5-FU)

Patients with known hypersensitivity to any component of bevacizumab

Patient has a known hypersensitivity to the components of study drugs, its analogues, or drugs of similar chemical or biologic composition

Known hypersensitivity to thalidomide or lenalidomide (if applicable)

Hypersensitivity to bortezomib, boron, or mannitol

Known or suspected hypersensitivity to azacitidine or mannitol

Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80

No history of hypersensitivity to bortezomib, boron or mannitol

History of Grade ? 3 infusion-associated AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine or acetaminophen

Known hypersensitivity to nab-paclitaxel or to gemcitabine or to any of the excipients.

Subject has known history of serious hypersensitivity reaction to a known ingredient of ASP8273, erlotinib or gefitinib.

Prior treatment with TAS4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in class

Known history of ? Grade 3 hypersensitivity to a therapeutic antibody.

Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), or ruxolitinib, or any of their excipients.

Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for idelalisib, obinutuzumab, or chlorambucil

Have known hypersensitivity to thalidomide or lenalidomide

Patient has hypersensitivity to bortezomib, boron, or mannitol

History of known hypersensitivity to S. cerevisiae, bevacizumab or any component of FOLFOX or FOLFIRI; hypersensitivity skin test is required at screening to rule out allergy to S. cerevisiae

History of hypersensitivity to durvalumab or any excipient

History of hypersensitivity to the combination or comparator agent

Known hypersensitivity to filgrastim or to Escherichia coli (E. coli) derived proteins

Subject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.

Patients with known hypersensitivity to thalidomide or lenalidomide or pomalidomide

Known hypersensitivity to any constituent of the study medication.

History of hypersensitivity to polysorbate 80

Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

No known hypersensitivity to any of the following agents: oxaliplatin, cisplatin, capecitabine, 5-flurouracil, docetaxel, or irinotecan

Hypersensitivity to polysorbate 80

Known hypersensitivity to idelalisib, its metabolites, or formulation excipients

Known hypersensitivity to nab-paclitaxel (Arm: idelalisib + nab-paclitaxel), their metabolites, or formulation excipients

Known hypersensitivity to 5-fluorouracil, leucovorin, or oxaliplatin (Arm: idelalisib + mFOLFOX6), their metabolites, or formulation excipients

Known hypersensitivity to any component of recombinant protein production by CHO cells

Subject has a known or suspected hypersensitivity to enzalutamide or any components of the formulation used.

History of hypersensitivity to 4-aminoquinoline compound

Known hypersensitivity to mannitol

Known hypersensitivity to the trial drugs, to their excipients or to contrast media

Hypersensitivity to the active substance or ingredients of PEGPH20 and docetaxel.

Known hypersensitivity to any of the components of RO6927005

Patients with contra-indication and/or history of severe hypersensitivity reactions to gemcitabine and/or nab-paclitaxel as mentioned in the locally approved label

Patients with a known hypersensitivity to buparlisib or to its excipients

Hypersensitivity to erlotinib, crizotinib or to any of the excipients

Known hypersensitivity to afatinib (BIBW 2992) or the excipients of any of the trial drugs

Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

Known hypersensitivity to 5-azacytidine\r\n* Prior treatment with 5-azacytidine is allowed

History of hypersensitivity to any of the study drugs or to any excipients.

Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), ruxolitinib, or any of their excipients.

Known hypersensitivity to dacarbazine (DTIC).

Patients with known hypersensitivity to any components of ME-344 or topotecan study drug product

History of iodine hypersensitivity

Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds

Known hypersensitivity to any inactive ingredient of bevacizumab

Known hypersensitivity to any inactive ingredient of TPI 287

Known hypersensitivity to recombinant proteins, or any component contained in the drug formulation

Known hypersensitivity to lithium or tretinoin

Known hypersensitivity to bevacizumab or any of its excipients or any other study drug

Patient has hypersensitivity to any of the components of study drugs.

Known hypersensitivity to thalidomide or lenalidomide

Has a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab;

Has a known hypersensitivity to baker's yeast or has an active yeast infection;

Patients with known hypersensitivity to any of the components of AN-152 including doxorubicin and LH-RH agonists

History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid

Subjects with known hypersensitivity to any components of ALKS 4230

Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)

Patients with hypersensitivity to amiodarone or NAC

Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

Patient must not have known sensitivity to terameprocol or any formulation excipients

Patients who were previously exposed and who developed severe adverse events, hypersensitivity or desquamating rash to either thalidomide or lenalidomide

Known hypersensitivity to any of the study drugs

History of hypersensitivity to IMiDs® (lenalidomide, pomalidomide, thalidomide).

Hypersensitivity to obinutuzumab

Known hypersensitivity to any of the study drugs involved

Known hypersensitivity to thalidomide or other immunomodulatory drugs.

Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients, or to bortezomib, boron, or mannitol

Known severe hypersensitivity to ketoconazole, calcitriol or any of the excipients of these products

Patients with known hypersensitivity or intolerance to melphalan

Known hypersensitivity to any component of study treatments that resulted in drug discontinuation

Have known allergies, hypersensitivity, or intolerance to docetaxel or dexamethasone or their excipients

Patient has a known hypersensitivity to dimethyl sulfoxide (DMSO) or murine or bovine proteins.

Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study

Patients with known prior severe hypersensitivity reactions to cabazitaxel or other agents containing polysorbate 80

Patient has a known hypersensitivity to any of the excipients of PQR309.

Known hypersensitivity to any of the treatment components of ramucirumab or LY2875358.

Hypersensitivity to PEG or other component of AEB1102 (Co-ArgI-PEG)

Subjects with porphyria’s or known hypersensitivity to porphyrins

Known hypersensitivity to any component of atezolizumab formulation or other study medication

Known hypersensitivity to any component of study treatments

Known hypersensitivity to any component of study treatments

Known hypersensitivity to bendamustine or mannitol

Known hypersensitivity to the components of niraparib

Known hypersensitivity to bevacizumab or any component of its formulation

Patient has a known hypersensitivity to any of the components of the study drug.

Known hypersensitivity to thalidomide or lenalidomide (if applicable)

Known hypersensitivity to any involved study drug or any of its formulation components

No known hypersensitivity to trastuzumab or pertuzumab

Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for ENTO

Have known allergies, hypersensitivity, or intolerance to enzalutamide or niclosamide or their excipients

History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g. monoclonal antibodies, polyclonal gamma globulin, polysorbates)

Known hypersensitivity to rosuvastatin

Subject has a known history of serious hypersensitivity to ASP2215, or any component of the formulation used.

Known hypersensitivity to the study investigational medicinal product (IMP), the metabolites, or formulation excipients

History of hypersensitivity (> Grade 2) to active or inactive excipients of AZD2014, drugs containing Cremophor, taxanes or structurally/chemically similar drugs

Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate or enzalutamide. History of hypersensitivity to docetaxel or polysorbate 80.

The subject has a history of severe hypersensitivity reactions to drugs formulated with polysorbate 80;

Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study

Known hypersensitivity to HDAC inhibitors or to any of the components of mocetinostat

Known hypersensitivity to gemcitabine

Known hypersensitivity to any of the components of AG-221

Patients in the combination arms - known hypersensitivity to fulvestrant

Known intolerance of or hypersensitivity to fosbretabulin

Known hypersensitivity or history of severe intolerance or toxicity to study-assigned chemotherapy. Note: History of severe hypersensitivity reactions to docetaxel (polysorbate 80-based formulations) for participants to be treated with MLN4924 + docetaxel; history of hypersensitivity to carboplatin for participants to be treated with MLN4924 + carboplatin + paclitaxel; or history of severe hypersensitivity to paclitaxel (Cremophor-based formulations) for participants to be treated with MLN4924 + carboplatin + paclitaxel in Part B.

Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin

Known hypersensitivity to any of the treatment ingredients. Known previous Grade 3-4 infusion related reactions with anti-EGFR mABs

Known hypersensitivity to thalidomide or Revlimid (if applicable)

Known hypersensitivity to any component of study treatments that resulted in drug discontinuation

No prior history of intolerance or hypersensitivity to trastuzumab and/or adverse events related to trastuzumab, murine proteins, or any of the excipients that resulted in trastuzumab being permanently discontinued

Known hypersensitivity to any components of the study drugs

Have known hypersensitivity to platinum (Pt) compounds

Known hypersensitivity to any component of study treatments

History of hypersensitivity to hydrogel

Patients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxel

Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study

Known hypersensitivity to thalidomide or lenalidomide

Hypersensitivity to recombinant human IL-2

Known hypersensitivity to carfilzomib

Patients with a known or suspected hypersensitivity to any of the components of OTS167.

Known hypersensitivity to any components of SC16LD6.5 study drug product.

Patient has hypersensitivity to bortezomib, boron, or mannitol

Known hypersensitivity to any of the study drugs or its excipients.

Known hypersensitivity to Tween-80, or human immunoglobulin

Known hypersensitivity to chlorambucil or any of its excipients

Known hypersensitivity to study-assigned chemotherapy

History of severe hypersensitivity reactions to docetaxel (polysorbate 80-based formulations) for patients to be enrolled in Arm 1 (MLN4924 + docetaxel), history of hypersensitivity to carboplatin for patients to be enrolled in Arm 2 (MLN4924 + paclitaxel + carboplatin), or history of severe hypersensitivity to paclitaxel (cremophor-based formulations) for patients to be enrolled in Arm 2

Known significant hypersensitivity to any components of study treatment

Have known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipients

Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the margetuximab drug formulation

History of intolerance (including grade 3 or 4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins

Known hypersensitivity to azacitidine or mannitol

Known hypersensitivity to compounds related to orteronel or to orteronel excipients

History of hypersensitivity to amikacin or other aminoglycosides

Subjects with hypersensitivity (not renal dysfunction or eye disorder) to CDV or to CMX001 or its excipients.

Subjects with known hypersensitivity to peptide drugs, including LHRH agonists.

Patients with a known or suspected hypersensitivity to either gemcitabine or any of the components of PRI-724.

Known or suspected hypersensitivity to azacitidine or mannitol

Known hypersensitivity to any study drug

Hypersensitivity to VELCADE, boron, mannitol, or any other component of protocol therapy

Hypersensitivity of AT13387 or other components of the drug product

Known hypersensitivity to bortezomib, boron, or mannitol

Known hypersensitivity to BKM120 or to its excipients

Known hypersensitivity to NSAIDs

History of hypersensitivity to taxanes or drug formulations containing Cremophor®.

Patients with known hypersensitivity to sorafenib or any other component of sorafenib.

Known hypersensitivity to lenalidomide or thalidomide

Known or suspected hypersensitivity to 5'-azacitidine or mannitol

Known hypersensitivity to the components of niraparib, PD-1 inhibitor, or their excipients

Known hypersensitivity to the components of niraparib or excipients

Known hypersensitivity to the active substance or to any of the excipients in the vaccine

Known hypersensitivity to any of the components of PRI-724

Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients

Patients with hypersensitivity to carfilzomib, Velcade, boron, or mannitol.

Known hypersensitivity to varenicline

Patients with known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients

Known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation

Known hypersensitivity to thalidomide

Patient has hypersensitivity to bortezomib, boron or mannitol

Known unmanageable allergies, hypersensitivity, intolerance to monoclonal antibodies, to murine, chimeric, human proteins or their excipients

Patient has hypersensitivity to brentuximab vedotin

Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen

Known allergies, hypersensitivity, or intolerance to trabectedin, dacarbazine, dexamethasone, or their excipients

Known allergies, hypersensitivity, or intolerance to dacarbazine does not apply

Hypersensitivity to the active substance, or any of the excipients of the eribulin drug product, or dacarbazine, (please refer to the dacarbazine prescribing information).

Hypersensitivity to thalidomide, lenalidomide, or dexamethasone

Known hypersensitivity to the study drugs

Known hypersensitivity to the study drugs

Patients with a known hypersensitivity to BKM120 or to its excipients

Known or suspected hypersensitivity to ofatumumab, bendamustine or mannitol.

Known hypersensitivity to thalidomide or everolimus (including other rapamycins, sirolimus and temsirolimus)

Suspected hypersensitivity to interferon alpha

Known history of dose-limiting hypersensitivity reactions to paclitaxel/Cremophor EL

Known hypersensitivity to polymyxin B

History of severe hypersensitivity reaction to drugs formulated with polysorbate 80

Known significant hypersensitivity to study drugs or excipients

Hypersensitivity to trial medications

Known hypersensitivity to bendamustine, mannitol, or other study-related drugs

Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 are excluded from participation

Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients

Hypersensitivity to azacitidine or mannitol

Known or suspected hypersensitivity to azacitidine or mannitol

Hypersensitivity to recombinant proteins or excipients in elotuzumab, lenalidomide, or dexamethasone.

Known severe hypersensitivity to or any of the excipients of this product.

History of allergies or known hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system

Known hypersensitivity to any of the study drugs

History of hypersensitivity to docetaxel or polysorbate 80

History of hypersensitivity reactions attributed to simvastatin

History of hypersensitivity to durvalumab or any excipient

Known hypersensitivity to ibrutinib or nivolumab

Known hypersensitivity to sirolimus

Subject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.

Known hypersensitivity to BGJ398, fluorouracil, oxaliplatin, irinotecan or to any of the excipients

Known hypersensitivity to any of the components of talazoparib

Known hypersensitivity to any component of RDHAP

Known hypersensitivity to microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide, magnesium stearate

Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds

Known hypersensitivity to human albumin

Have known hypersensitivity to pancuronium bromide, atracurium or cisatracurium,

Have known hypersensitivity to ciprofloxacin or any member of the quinolone class of antimicrobial agents,

Patient has a known hypersensitivity to any of the excipients of BKM120

Patient has prior hypersensitivity reaction or intolerance to docetaxel or other drugs formulated with polysorbate 80

No known serious or severe hypersensitivity reaction to naloxegol or any of its excipients

Have a known hypersensitivity to olanzapine or to phenothiazines

History of hypersensitivity to other psychostimulants

Patients known to have hypersensitivity to dacarbazine (DTIC) are not eligible

Known diagnosis of hypocortisolism

Known hypersensitivity to somatostatin analogs or any component of the pasireotide long acting release (LAR) or suspension concentrate (s.c.) formulations

Have known hypersensitivity to anthracycline compounds or any excipient in NC-6300.

Known hypersensitivity to thalidomide or lenalidomide (if applicable)

Known hypersensitivity or idiosyncratic reaction to any of the study drugs (Sodium Cridanimod, megestrol acetate, lidocaine) and excipients;

Has a history of severe hypersensitivity reaction to pembrolizumab, Cisplatin or radiotherapy or their analogs

Known or suspected hypersensitivity to any of the talazoparib capsule components.

Known or suspected hypersensitivity to any of the talazoparib capsule components.

Known hypersensitivity to any component of the atezolizumab product

Known hypersensitivity to cold

History hypersensitivity to opioids.

Patient with known hypersensitivity to rocuronium, sugammadex or its components.

History of hypersensitivity or reaction to N-methyl-D-aspartate (NMDA) receptor antagonists

Prior carboplatin or oxaliplatin hypersensitivity reaction

Patient has a history of hypersensitivity to fentanyl or opioids

Major contraindications to anamorelin e.g. hypersensitivity

PATIENTS: History of hypersensitivity to haloperidol or chlorpromazine

Patients with a known hypersensitivity reaction to 5-HT3 receptor antagonists or NK1 receptor antagonists

Known hypersensitivity reaction to any component of ferric carboxymaltose

Patient has a known hypersensitivity to the administration of any prescribed oral or intravenous study medication or metabolite, including but not limited to, a history of hypersensitivity to the drugs or their components, severe renal impairment, severe bone marrow suppression, or systemic infection

Hypersensitivity to pregabalin

History of hypersensitivity to pregabalin or gabapentin

History of hypersensitivity or severe intolerance to azoles

Hypersensitivity to ginseng

Patients with known hypersensitivity to octreotide or somatostatin

Patients with known hypersensitivity to NT-I7 or any component used in the vehicle/formulation are ineligible

Patients with a history of echinocandin or fluconazole hypersensitivity are not eligible

Patients with a history of echinocandin or azole hypersensitivity are not eligible

Participants with known hypersensitivity to modafinil, armodafinil, or any of its components

Known hypersensitivity to any component of bevacizumab

Known hypersensitivity to any component of testosterone

History of hypersensitivity to all of the following antibiotics: penicillin, erythromycin, clindamycin, and any fluoroquinolone

Known or suspected hypersensitivity or intolerance to fentanyl or hydromorphone or excipients in the study medications

Known or suspected hypersensitivity to any of the constituents of the investigational product

History of hypersensitivity to any excipients in the quizartinib/placebo tablets;

Known hypersensitivity to thalidomide or lenalidomide

Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGD009

Known hypersensitivity to ASN002 or its excipients;

Prior history of hypersensitivity to milk proteins

Patients with hypersensitivity to any tetracycline

Any known hypersensitivity to dexmedetomidine

History of hypersensitivity to haloperidol or benzodiazepine

Patients with hypersensitivity to tetracyclines

Minocycline trial only: patients with hypersensitivity to any tetracyclines

Patients with previous history of hypersensitivity to ribavirin or its components

No history of severe hypersensitivity reactions to drugs or other causes (e.g., beestings)

Known hypersensitivity to recombinant ESAs or the excipients contained within the investigational product.

Hypersensitivity to dexamethasone or corticosteroids or Equal sugar substitute

Patients with known hypersensitivity to sildenafil or other ingredients of sildenafil

Known hypersensitivity to paclitaxel, Cremophor EL, or iodinated contrast media

Subjects with a history of hypersensitivity or idiosyncratic reactions to azole agents

History of hypersensitivity to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason

Documented hypersensitivity to any component of ranolazine (Ranexa) pills

Previous medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients.

Patients must not have known hypersensitivity to eflornithine or sulindac or the excipients byproducts; patients must not have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal antiinflammatory drugs (NSAIDs)

Patient has a known history of hypersensitivity to defibrotide or any of the excipients.

History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein

History of known latex hypersensitivity

Known hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO)

History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein

History of known latex hypersensitivity

Known allergies, hypersensitivity, or intolerance to any of the study medications.

History of hypersensitivity or idiosyncratic reactions to azoles

Patient has a known hypersensitivity to the administration of rolapitant or its excipients

Known hypersensitivity to NAC

Patients who have hypersensitivity to sitagliptin

Known hypersensitivity to cyclophosphamide or any of its metabolites

Known hypersensitivity to one or more of the study agents

Known hypersensitivity to any component of the MPDL3280A or rociletinib formulations or history or hypersensitivity to chimeric humanized antibodies or fusion proteins

History of hypersensitivity reaction to Xolair or any ingredient of Xolair

Known or suspected hypersensitivity to azacitidine, mannitol, its constituents, or to any other humanized monoclonal antibody

Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)

Patients with a known hypersensitivity to olaparib or any of the excipients of the product

Known severe hypersensitivity to paclitaxel

History of hypersensitivity to durvalumab, tremelimumab or any excipient

Known hypersensitivity to any component of the nivolumab or ipilimumab product

History of hypersensitivity to taxanes; hypersensitivity to the solvent does not preclude patient participation in this Study

History of hypersensitivity or unexpected reactions to capecitabine, other fluoropyrimidine agents, or any of their ingredients

Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies, hyaluronidase, or other human proteins, or their excipients, or known sensitivity to mammalian-derived products

History of hypersensitivity to ribociclib or any of its components

Patients with hypersensitivity to bortezomib, boron or mannitol

Patients with hypersensitivity to bortezomib, boron or mannitol

Has suspected or known hypersensitivity to ingredients of MK-8228 (letermovir) formulations